-
-
-
-
-
-
-
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
-
-
-
-
-
-
-
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
-
-
-
-
-
-
-
Scinai publishes peer-reviewed data supporting PC111 therapy for skin diseases
-
-
-
-
-
-
-
Scinai Announces Annual Financial Results for 2024
-
-
-
-
-
-
-
Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences
-
-
-
-
-
-
-
Scinai Immunotherapeutics (SCNI) Regains Nasdaq Compliance
-
-
-
-
-
-
-
Scinai Immunotherapeutics (SCNI) announces promising results in an in-vivo proof-of-concept psoriatic human skin model
-
1,157,753 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

